NCT04240704 - Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 7, 2020

Primary Completion Date

September 5, 2024

Study Completion Date

September 5, 2024

Conditions

Non-Hodgkins LymphomaChronic Lymphocytic Leukemia

Interventions

DRUG

JBH492

Anti-CCR7 antibody-drug conjugate (ADC)

Trial Locations (8)

Novartis Investigative Site, Freiburg im Breisgau

Novartis Investigative Site, Singapore

Novartis Investigative Site, Tel Aviv

Novartis Investigative Site, Helsinki

Novartis Investigative Site, Dresden

Novartis Investigative Site, Chuo Ku

Novartis Investigative Site, Seoul

Novartis Investigative Site, Barcelona